Oncternal Therapeutics Inc Forecast, price target & analysts
Oncternal Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Oncternal Therapeutics Inc Classifications & Recommendation:
Oncternal Therapeutics Inc Price Target
| Target Price | $2.04 |
| Price | $0.53 |
| Potential |
287.39%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Oncternal Therapeutics Inc 2026 .
The average Oncternal Therapeutics Inc target price is $2.04.
This is
287.39%
register free of charge
$2.10
298.78%
register free of charge
$2.02
283.59%
register free of charge
|
|
| A rating was issued by 6 analysts: 0 Analysts recommend Oncternal Therapeutics Inc to buy, 3 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Oncternal Therapeutics Inc stock has an average upside potential 2026 of
287.39%
register free of charge
|
Sales and Margin forecast 2024, 2025 & 2026
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.79 | 1.68 |
| 46.98% | 112.41% | |
| Net Margin | -4,997.47% | -2,138.45% |
| 68.58% | 57.21% |
4 Analysts have issued a sales forecast Oncternal Therapeutics Inc 2024 . The average Oncternal Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
4 Oncternal Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Oncternal Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -13.43 | -12.12 |
| 20.06% | 9.75% | |
| P/E | negative |
4 Analysts have issued a Oncternal Therapeutics Inc forecast for earnings per share. The average Oncternal Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Oncternal Therapeutics Inc...
Current Oncternal Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Brookline Capital |
Locked
➜
Locked
|
Locked | Sep 12 2024 |
| Northland Capital Markets |
Locked
➜
Locked
|
Locked | Sep 12 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Brookline Capital:
Locked
➜
Locked
|
Sep 12 2024 |
|
Locked
Northland Capital Markets:
Locked
➜
Locked
|
Sep 12 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
